Vanda Pharmaceuticals Inc.
$16.9M 38,897 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Janssen Pharmaceuticals, Inc
Janssen Pharmaceuticals, Inc reported $16,838,366.74 across General Payments, Research, and Ownership to 169,360 physicians and teaching hospitals across 169,416 transactions.
- $16.8M Top 10% payer
- All-tracks total
- 169,416 Top 1% volume
- Transactions
- 169,360 Top 1% reach
- Recipients
- +$197.7K
- General Payments vs PY2023
Janssen Pharmaceuticals, Inc reported $16,838,366.74 across all CMS Open Payments tracks (General + Research + Ownership) to 169,360 physicians and teaching hospitals in Program Year 2024 - ranking #109 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $16,109,201.74, averaging $99.42 per recipient.
How Janssen Pharmaceuticals, Inc's $16.8M all-tracks total breaks down
Janssen Pharmaceuticals, Inc's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
100/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer janssen-pharmaceuticals-inc Janssen Pharmaceuticals, Inc
$16.8M · #109/1,925 · 0.1% industry · PY2024
- TOT $16.8M
- RANK #109
- SHARE 0.1%
- TXN 169,416
- RCP 169,360
- CAT 9
- GEN $16.1M
- ΔGEN +$197.7K
- TOP1 0.8%
- PY 2024
Volume peers
Nearest volume peer: Vanda Pharmaceuticals Inc. ($16.9M)
Janssen Pharmaceuticals, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Janssen Pharmaceuticals, Inc's CMS-reported General Payments increased by $197.7K (+1.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: JANSSEN PHARMACEUTICALS, INCPY2023: JANSSEN PHARMACEUTICALS, INCPY2024: Janssen Pharmaceuticals, Inc. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $15,911,529.38
- PY2024
- $16,109,201.74
What the Data Shows for Janssen Pharmaceuticals, Inc
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Janssen Pharmaceuticals, Inc, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
3,195 transactions worth $8.9M make "Compensation for Services Other Than Consulting" the top general-payment category in the 9-category breakdown below, 55.4% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 9 types of general payments, Janssen Pharmaceuticals, Inc's largest category was "Compensation for Services Other Than Consulting" at $8.9M - 55.4% of General Payments.
Janssen Pharmaceuticals, Inc reports 9 general-payment categories - the top three are Compensation for Services Other Than Consulting (55.4%), Food and Beverage (28.9%), and Travel and Lodging (8.7%). The remaining 6 categories make up 7.0% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Janssen Pharmaceuticals, Inc files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Janssen Pharmaceuticals, Inc divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $8.9M | 3,195 | 55.4% |
| Food and Beverage | $4.7M | 159,948 | 28.9% |
| Travel and Lodging | $1.4M | 5,544 | 8.7% |
| Consulting Fee | $836.6K | 282 | 5.2% |
| Space Rental or Facility Fees | $124.6K | 56 | 0.8% |
| Acquisitions | $79.9K | 1 | 0.5% |
| Grant | $61.5K | 3 | 0.4% |
| Gift | $12.4K | 2 | 0.1% |
| Education | $8.7K | 329 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $621,435.96 (3.9%) of $16,109,201.74 in this company's General Payments records across 59,837 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Janssen Pharmaceuticals, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Hannah E Phillips
$128,406.82 across 102 reported transactions
- 2
Maher O Ayyash
$123,822.18 across 192 reported transactions
- 3
George C Kruse
$123,425.88 across 151 reported transactions
- 4
Sanford Herman
$123,258.09 across 164 reported transactions
- 5
Carolyn M Rekerdres
$122,522.99 across 133 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Janssen Pharmaceuticals, Inc ranks #109 of 1,925 by total payments (top 6% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,802 of 1,838 by HHI (bottom 2% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Inogen, Inc. : $40.6K total payments, HHI 32
- Hospira, Inc. : $21.6K total payments, HHI 31
- Hydrofera LLC : $38.2K total payments, HHI 31
- Galderma Laboratories, L.P. : $16.5M total payments, HHI 29
- Medicomp Inc : $19.9K total payments, HHI 28
- Watermark Medical, Inc. : $9.7K total payments, HHI 26
- Janssen Pharmaceuticals, Inc (this company) : $16.1M total payments, HHI 25
- A-dec, Inc. : $1.8M total payments, HHI 24
- Revance Therapeutics, Inc. : $1.2M total payments, HHI 24
- Alvogen Inc : $19.0K total payments, HHI 24
- OptumHealth Care Solutions, LLC : $44.5K total payments, HHI 24
- Medical Device Business Services, Inc. : $24.4M total payments, HHI 24
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Janssen Pharmaceuticals, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Janssen Pharmaceuticals, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Janssen Pharmaceuticals, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ipsen Biopharmaceuticals, Inc
$16.8M 20,198 recipients
Compare payment profiles
Seqirus USA Inc
$16.7M 6,517 recipients
Compare payment profiles
Endotronix, Inc.
$17.0M 179 recipients
Compare payment profiles
Align Technology, Inc.
$17.0M 55,540 recipients
Compare payment profiles
GastroGPO, LLC
$16.6M 8 recipients
Compare payment profiles
Put this to use
Janssen Pharmaceuticals, Inc ranks #109 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Janssen Pharmaceuticals, Inc sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Janssen Pharmaceuticals, Inc. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.